The Group, Which Makes Chemicals Used in Products From Animal Feed to Pfizer and BioNTech's Covid Vaccine, Announced up to 2,000 Job Cuts by 2026 Dec 13 (Reuters) - Germany's Evonik Evkn.de Plans to Restructure Its Business Lines Into Two Segments, It Said on Friday.
12月13日（路透社）- 德國的Evonik Evkn.de 該公司週五表示，計劃將其業務線重組爲兩個部分。
From April 1, the Group Will Focus on Its Two Core Operating Businesses: Custom Solutions and Advanced Technologies.
從4月1日起，該集團將專注於其兩個核心經營業務：定製解決方案和愛文思控股。
Evonik's Custom Solutions Segment Includes Additives for Paints and Coatings, as Well as Products for the Cosmetics and Pharmaceutical Industries. Its Advanced Technologies Segment Focuses Mostly on High Performance Polymers and Hydrogen Peroxide Production.
Evonik的定製解決方案部分包括用於塗料和塗層的添加劑，以及化妝品和藥品行業的產品。其愛文思控股部分主要集中在高性能聚合物和過氧化氫的生產上。
By the End of 2026, Evonik Plans to Reduce the Number of Management Levels From an Average of 10 to a Maximum of Six Across the Group, in Line With Its "Tailor Made" Reorganisation Programme.
到2026年底，Evonik計劃將管理層級數從平均10級減少到最多6級，以符合其"量身定製"的重組方案。
The Group, Which Makes Chemicals Used in Products From Animal Feed to Pfizer and BioNTech's Covid Vaccine, Announced up to 2,000 Job Cuts by 2026 In March With the Goal of Reducing Costs by 400 Million Euros ($437.3 Million) Annually.
該集團製造的化學品用於從動物飼料到輝瑞和BioNTech的Covid生物-疫苗的產品，預計到2026年裁員最多達2000個職位。 在三月 目標是每年減少40000萬歐元（約43730萬）的成本。
Germany's Chemicals Industry Suffered Heavily Throughout 2023 Due to High Production Costs and Weak Demand Amid Rising Inflation. Initial Signs of Recovery in the First Quarter of This Year Have Begun to Fade Away.
由於高昂的生產成本和需求疲軟，德國的化學品行業在2023年受到嚴重影響，面臨着不斷上升的通貨膨脹。今年第一季度的初步復甦跡象已經開始消退。
(Reporting by Anastasiia Kozlova and Amir Orusov, Editing by Friederike Heine)
（撰稿：Anastasiia Kozlova 和 Amir Orusov，編輯：Friederike Heine）
((Anastasiia.kozlova@Thomsonreuters.com; Amir.orusov@Thomsonreuters.com))
（（Anastasiia.kozlova@Thomsonreuters.com；Amir.orusov@Thomsonreuters.com））
